Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells

Guido Bocci (1) , Anna Fioravanti (1) , Concettina La Motta (2) , Paola Orlandi (1) , Bastianina Canu (1) , Teresa Di Desidero (1) , Laura Mugnaini (2) , Stefania Sartini (2) , Sandro Cosconati (3) , Rita Frati (1) , Alessandro Antonelli (1) , Piero Berti (4) , Paolo Miccoli (4) , Federico da Settimo (2) , Romano Danesi (1)

1 Department of Internal Medicine
2 Department of Pharmaceutical Sciences
3 Department of Pharmaceutical Chemistry and Toxicology
4 Department of Surgery

To demonstrate the antiproliferative and pro-apoptotic activity of the novel pyrazolopyrimidine derivative multiple tyrosine kinase inhibitor CLM3, alone and in combination with SN-38 (the active metabolite of irinotecan), on endothelial and tumour cells and to show its mechanism of action.

Mots clés: CLM3; irinotecan; angiogenesis; synergism; tyrosine kinase inhibitor

Domaines: Pharmacologie

Guido Bocci, Anna Fioravanti, Concettina La Motta, Paola Orlandi, Bastianina Canu, et al.. Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells. Biochemical Pharmacology, 2011, ⟨10.1016/j.bcp.2011.03.022⟩. ⟨hal-00693835⟩